A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

March 28, 2023

Study Completion Date

September 13, 2023

Conditions
Geographic Atrophy
Interventions
DRUG

ANX007

Form: solution for injection; Route of Administration: IVT

OTHER

Sham comparator

Form and Route of Administration: pressure to mimic IVT injection

Trial Locations (53)

2000

Site 44, Sydney

Site 47, Sydney

2022

Site 49, Bondi Junction

2067

Site 46, Chatswood

2100

Site 45, Brookvale

5000

Site 48, Adelaide

6011

Site 51, Wellington

8014

Site 50, Christchurch

19107

Site 27, Philadelphia

21740

Site 1, Hagerstown

Site 41, Hagerstown

22903

Site 14, Charlottesville

23502

Site 25, Norfolk

28803

Site 20, Asheville

30909

Site 42, Augusta

32216

Site 53, Jacksonville

32503

Site 26, Pensacola

33711

Site 28, St. Petersburg

33782

Site 16, Pinellas Park

33880

Site 6, Winter Haven

33907

Site 12, Fort Myers

34233

Site 43, Sarasota

40509

Site 11, Lexington

44195

Site 52, Cleveland

48073

Site 29, Royal Oak

73013

Site 13, Edmond

75231

Site 21, Dallas

76028

Site 34, Burleson

76102

Site 32, Fort Worth

76104

Site 22, Fort Worth

77401

Site 24, Bellaire

77494

Site 35, Katy

78240

Site 54, San Antonio

Site 8, San Antonio

78750

Site 4, Austin

79606

Site 15, Abilene

85053

Site 5, Phoenix

87109

Site 30, Albuquerque

89502

Site 10, Reno

90211

Site 2, Beverly Hills

91107

Site 23, Pasadena

92064

Site 37, Poway

92705

Site 18, Santa Ana

93309

Site 31, Bakersfield

94040

Site 19, Mountain View

94598

Site 33, Walnut Creek

95825

Site 17, Sacramento

97401

Site 40, Eugene

06385

Site 39, Waterford

02114

Site 36, Boston

01107

Site 3, Springfield

07003

Site 38, Bloomfield

08034

Site 9, Cherry Hill

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY

NCT04656561 - A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy | Biotech Hunter | Biotech Hunter